SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

SAN

92.06

+2.59%↑

SHL.DE

49.22

+0.94%↑

ARGX

503

+3.65%↑

FRE

42.91

+0.73%↑

ONC.US

228.61

+1.33%↑

Search

Pharming Group NV

Geschlossen

0.852 2.9

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.819

Max

0.863

Schlüsselkennzahlen

By Trading Economics

Einkommen

4.3M

3.4M

Verkäufe

18M

93M

EPS

-0.02

Gewinnspanne

3.657

Angestellte

404

EBITDA

1.9M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+140.91% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

119M

609M

Vorheriger Eröffnungskurs

-2.05

Vorheriger Schlusskurs

0.852

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Mai 2025, 19:39 UTC

Wichtige Markttreiber

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16. Mai 2025, 23:18 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16. Mai 2025, 22:30 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- Update

16. Mai 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16. Mai 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Mai 2025, 21:54 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- WSJ

16. Mai 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16. Mai 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16. Mai 2025, 21:17 UTC

Top News

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16. Mai 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16. Mai 2025, 20:55 UTC

Akquisitionen, Fusionen, Übernahmen

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. Mai 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

16. Mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. Mai 2025, 20:37 UTC

Top News

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16. Mai 2025, 20:33 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16. Mai 2025, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16. Mai 2025, 20:18 UTC

Top News

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16. Mai 2025, 20:16 UTC

Top News

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16. Mai 2025, 20:15 UTC

Ergebnisse

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16. Mai 2025, 20:11 UTC

Akquisitionen, Fusionen, Übernahmen

Henry Schein: William K. Daniel Joins Board

16. Mai 2025, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

Henry Schein: Strategic Investment by KKR Completed

16. Mai 2025, 20:05 UTC

Akquisitionen, Fusionen, Übernahmen

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. Mai 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16. Mai 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16. Mai 2025, 18:51 UTC

Top News

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16. Mai 2025, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16. Mai 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16. Mai 2025, 18:35 UTC

Top News

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16. Mai 2025, 18:32 UTC

Top News

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16. Mai 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Peer-Vergleich

Kursveränderung

Pharming Group NV Prognose

Kursziel

By TipRanks

140.91% Vorteil

12-Monats-Prognose

Durchschnitt 2 EUR  140.91%

Hoch 2 EUR

Tief 2 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pharming Group NV – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.